Freeman Chris 4

Accession 0001871615-26-000002

CIK 0001576280other

View on SEC.gov Company Profile

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 5:59 PM ET

Size

24.6 KB

Accession

0001871615-26-000002

Insider Transaction Report

Form 4

Period: 2026-01-01

Guardant Health, Inc.GH

Freeman Chris

Chief Commercial Officer

Transactions

Exercise/Conversion
Common Stock
2026-01-01+1,928→ 28,723 total
Exercise/Conversion
Common Stock
2026-01-01+15,428→ 44,151 total
Exercise/Conversion
Common Stock
2026-01-01+1,667→ 45,818 total
Exercise/Conversion
Common Stock
2026-01-01+5,688→ 51,506 total
Exercise/Conversion
Common Stock
2026-01-01+2,526→ 54,032 total
Tax Payment
Common Stock
2026-01-01$102.14/sh−10,162$1,037,947→ 43,870 total
Exercise/Conversion
Restricted Stock Units
2026-01-01−1,928→ 5,786 total
Exercise: $0.00→ Common Stock (1,928 underlying)
Exercise/Conversion
Performance-Based Restricted Stock Units
2026-01-01−15,428→ 0 total
Exercise: $0.00→ Common Stock (15,428 underlying)
Exercise/Conversion
Restricted Stock Units
2026-01-01−1,667→ 5,002 total
Exercise: $0.00→ Common Stock (1,667 underlying)
Exercise/Conversion
Performance-Based Restricted Stock Units
2026-01-01−5,688→ 5,688 total
Exercise: $0.00→ Common Stock (5,688 underlying)
Exercise/Conversion
Restricted Stock Units
2026-01-01−2,526→ 17,684 total
Exercise: $0.00→ Common Stock (2,526 underlying)

Holdings

Performance-Based Restricted Stock Units
Exercise: $0.00→ Common Stock (15,428 underlying)
15,428

Footnotes (7)

[F1]These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
[F2]This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter.
[F3]Not applicable for Restricted Stock Units.
[F4]This represents a performance-based restricted stock unit award granted on June 7, 2023, with a performance metric and 2-year vest period that was achieved. The shares vested on January 1, 2026.
[F5]This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
[F6]This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027.
[F7]This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Documents

1 file

4
wk-form4_1767653972.xmlPrimary
FORM 4

Issuer

Guardant Health, Inc.

CIK 0001576280

→

Entity typeother

Related Parties

filerCIK 0001871615

Filing Metadata

Form type: 4
Filed: Jan 4, 7:00 PM ET
Accepted: Jan 5, 5:59 PM ET
Size: 24.6 KB

View on SEC.gov